Induction therapy in renal transplant recipients: how convincing is the current evidence?

Abstract:

:The goal of organ transplantation is to provide durable organ function while minimizing risks such as infection and cancer. Induction therapy in renal transplantation provides improved short- and long-term graft outcomes compared with placebo. Three agents are currently available and widely used in the US; rabbit anti-thymocyte globulin (rATG), basiliximab and alemtuzumab. These agents are all clinically effective in transplantation. In patients at high risk of rejection, graft outcomes are improved with the use of depleting agents, such as rATG or alemtuzumab, rather than basiliximab. Depleting agents are associated with more complications, such as infection and malignancy. The risk-benefit analysis for low-risk patients indicates that basiliximab may be the preferred agent in this population. Use of induction therapy, particularly with rATG, may not only allow for but also mandate reduction of maintenance immunosuppression. The mechanisms by which induction agents lead to improved clinical outcomes have not been elucidated. rATG and alemtuzumab lead to prompt and durable lymphocyte depletion, but many other mechanisms contribute to their suppression of alloimmunity. For instance, rATG contains antibodies specific for multiple adhesion molecules and even human leukocyte antigen, while CD52 (the target of alemtuzumab) is present on many antigen-presenting cells as well as lymphocytes. The manner in which the immune system recovers after induction may also aid in establishment of immune tolerance, with proliferation of suppressor T lymphocytes seen with rATG use. The various contributions of these mechanisms in achieving the goal of allograft tolerance are currently being investigated. The currently available data are of generally low quality, based on many small and often retrospective studies. Definitions of 'high risk' vary between studies, as do induction and maintenance dosing regimens. Standardization of definitions and establishment of large, prospective, multicentre trials would lead to a better understanding of the currently available agents and their best use in renal transplantation induction therapy.

journal_name

Drugs

journal_title

Drugs

authors

Wagner SJ,Brennan DC

doi

10.2165/11631300-000000000-00000

subject

Has Abstract

pub_date

2012-03-26 00:00:00

pages

671-83

issue

5

eissn

0012-6667

issn

1179-1950

pii

3

journal_volume

72

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Management of restless legs syndrome in patients on dialysis.

    abstract::Restless legs syndrome (RLS) is characterised by an urge to move the legs, uncomfortable sensations in the legs and worsening of these symptoms during rest with at least temporary relief brought on by activity. RLS occurs in 3-15% of the general population and in 10-30% of patients on maintenance dialysis. RLS may lea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666050-00003

    authors: Molnar MZ,Novak M,Mucsi I

    更新日期:2006-01-01 00:00:00

  • Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.

    abstract::Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00013

    authors: Wiseman LR,Markham A

    更新日期:1996-10-01 00:00:00

  • Oxantel-pyrantel in various regimens for the treatment of soil transmitted helminthiasis in rural and urban communities.

    abstract::204 individuals from a rural community were given a single dose of oxantel-pyrantel at 15mg/kg bodyweight and if still infected, 20mg/kg bodyweight, with cure rates of 100%, 53% and 71% for ascariasis, trichuriasis and hookworm infection, respectively. From an urban community, 124 patients were given the same drug eit...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-197800151-00016

    authors: Cabrera BD,Sy FS

    更新日期:1978-01-01 00:00:00

  • Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

    abstract::During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescripti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11635860-000000000-00000

    authors: Bannwarth B

    更新日期:2012-09-10 00:00:00

  • Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.

    abstract::Despite well known complications, oral nonsteroidal anti-inflammatory drugs (NSAIDs) remain the most commonly prescribed medications in the US for musculoskeletal disorders such as osteoarthritis. Although there has been a recent focus on the cardiovascular and renal complications associated with these agents, NSAID g...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11633740-000000000-00000

    authors: Roth SH

    更新日期:2012-05-07 00:00:00

  • Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

    abstract::As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0481-z

    authors: Longoria TC,Tewari KS

    更新日期:2015-11-01 00:00:00

  • Heparin Therapy: regimens and management.

    abstract::Heparin remains the most effective antithrombotic drug. It acts by combining with plasma antithrombin, thereby accelerating the neurtalisation of thrombin and other acitvated coagulation factors. Full-dose intravenous heparin is indicated in all cases of pulmonary embolism and established deep venous thrombosis, unles...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197713010-00005

    authors: Deykin D

    更新日期:1977-01-01 00:00:00

  • Pimavanserin: First Global Approval.

    abstract::Pimavanserin (Nuplazid™) is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist and antagonist developed by ACADIA Pharmaceuticals that has been approved in the US as a treatment for patients with hallucinations and delusions associated with Parkinson's disease psychosis. Up to 60 % of patients with ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-016-0597-9

    authors: Markham A

    更新日期:2016-07-01 00:00:00

  • Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci.

    abstract::The prevalence of penicillin-resistant pneumococci is increasing worldwide. Methods for susceptibility testing, as well as in vitro susceptibility of penicillin-susceptible and -resistant strains to new and existing agents (including oral and parenteral streptogramins), are described. For all specimens except CSF, oxa...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199600511-00003

    authors: Appelbaum PC

    更新日期:1996-01-01 00:00:00

  • Landiolol: A Review in Tachyarrhythmias.

    abstract::Intravenous landiolol [Rapibloc® (EU)], an ultra short-acting highly cardioselective β1-blocker, is approved in the EU for the rapid short-term control of tachyarrhythmias in the perioperative and intensive care settings. It has long been used in Japan to treat perioperative tachyarrhythmias. The efficacy of landiolol...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0883-9

    authors: Syed YY

    更新日期:2018-03-01 00:00:00

  • Brexpiprazole: First Global Approval.

    abstract::Brexpiprazole (Rexulti®) is an atypical antipsychotic that has been developed by Otsuka Pharmaceutical Co. Ltd and H. Lundbeck A/S as an oral treatment for several psychiatric disorders. Brexpiprazole is a novel serotonin-dopamine activity modulator that acts as a partial agonist of serotonin 1A (5-HT1A) and dopamine ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0462-2

    authors: Greig SL

    更新日期:2015-09-01 00:00:00

  • Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer.

    abstract::Patients with oncogene-driven lung cancer have limited therapeutic options after progressing on their targeted tyrosine kinase inhibitor (TKI) therapy. Given the growing role of immune checkpoint inhibitor (ICI) therapy in the treatment of lung cancer, oncogene-driven cancer has warranted further evaluation regarding ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01320-0

    authors: Somasundaram A,Socinski MA,Villaruz LC

    更新日期:2020-06-01 00:00:00

  • Issues in patient compliance.

    abstract::Patient compliance refers to the willingness and ability of an individual to follow health-related advice, to take medication as prescribed, to attend scheduled clinic appointments and to complete recommended investigations. It is a major health issue, with outcomes related to levels of morbidity, mortality and cost u...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754060-00002

    authors: Murphy J,Coster G

    更新日期:1997-12-01 00:00:00

  • Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

    abstract::Sodium-glucose co-transporter 2 (SGLT2) inhibitors are glucose-lowering drugs that reduce plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, thus resulting in glucosuria. Their effects consequently include reductions in HbA1c, blood glucose levels, and blood pressure, but also reductio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-1057-0

    authors: Pereira MJ,Eriksson JW

    更新日期:2019-02-01 00:00:00

  • Anidulafungin, a new echinocandin: in vitro activity.

    abstract::Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furtherm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11315560-000000000-00000

    authors: Morace G,Borghi E,Iatta R,Montagna MT

    更新日期:2009-01-01 00:00:00

  • Pharmacotherapy and weight-loss supplements for treatment of paediatric obesity.

    abstract::Childhood obesity has become the most common paediatric disorder in the developed world. Treatment of obesity in children may include lifestyle interventions, pharmacotherapy and weight-loss supplements. The outcome of lifestyle interventions, which classically include dietary modifications, increased activity and beh...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11319210-000000000-00000

    authors: Rogovik AL,Chanoine JP,Goldman RD

    更新日期:2010-02-12 00:00:00

  • Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.

    abstract::Exenatide extended-release (exenatide ER) [Bydureon(®)] is a glucagon-like peptide-1 receptor agonist, approved for the treatment of type 2 diabetes mellitus. It is injected subcutaneously by patients once weekly, with no dose titration required. This article updates an earlier review of exenatide ER in the management...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0420-z

    authors: Syed YY,McCormack PL

    更新日期:2015-07-01 00:00:00

  • The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

    abstract::Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic ac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11640880-000000000-00000

    authors: Angiolillo DJ

    更新日期:2012-11-12 00:00:00

  • Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update.

    abstract::Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767180-00006

    authors: Van Hoecke H,Vandenbulcke L,Van Cauwenberge P

    更新日期:2007-01-01 00:00:00

  • [Properties and features of nabumetone].

    abstract::Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the 2,6-disubstituted naphthylalkanone class. It is a prodrug metabolised to an active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA), which preferentially inhibits cyclo-oxygenase-2 (COX-2) and has both anti-inflammatory and analgesic properties. The...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Davies NM,McLachlan AJ

    更新日期:2000-01-01 00:00:00

  • Management of onychomycoses.

    abstract::Onychomycoses, infections of the nail caused by fungi, are amongst the most common illnesses. Because of the high incidence of these infections and problems involved in their therapy, they have received much attention, particularly as concerns a better characterisation of the causative micro-organisms. Onychomycosis c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958020-00005

    authors: Niewerth M,Korting HC

    更新日期:1999-08-01 00:00:00

  • Concentration of sulbactam and ampicillin in serum and the myometrium.

    abstract::Sulbactam 1g and ampicillin 2g were administered intravenously to 12 patients, and concentrations of the drugs were determined in the serum and myometrium for up to 120 minutes after infusion. The ratio of sulbactam to ampicillin was about 1:2 in the serum and myometrium. Both drugs penetrated well into the myometrium...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600312-00007

    authors: Schwiersch U,Lang N,Wildfeuer DA

    更新日期:1986-01-01 00:00:00

  • A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children.

    abstract::The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 m...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300461-00059

    authors: Polidori G,Titti G,Pieragostini P,Comito A,Scaricabarozzi I

    更新日期:1993-01-01 00:00:00

  • Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

    abstract:UNLABELLED:Ofloxacin is an established fluoroquinolone agent which achieves good concentrations in genitourinary tract tissues and fluids. It has good in vitro activity against most Enterobacteriaceae, Staphylococcus saprophyticus, methicillin-susceptible S. aureus, Neisseria gonorrhoeae, Chlamydia trachomatis and Haem...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00015

    authors: Onrust SV,Lamb HM,Balfour JA

    更新日期:1998-11-01 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00

  • Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

    abstract::Cefdinir (Omnicef) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus pneumoniae, the most common...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464130-00004

    authors: Perry CM,Scott LJ

    更新日期:2004-01-01 00:00:00

  • Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.

    abstract::In type 1 and 2 diabetes mellitus patients, hyperglycaemia is independently related to the development of microvascular and macrovascular complications. Glycaemic targets and the benefits of intensive versus conventional glucose control are under debate. The purpose of this review is to provide an overview of the rand...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11585220-000000000-00000

    authors: Mattila TK,de Boer A

    更新日期:2010-12-03 00:00:00

  • 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

    abstract:UNLABELLED:5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous photosensitivi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856040-00015

    authors: McNeely W,Goa KL

    更新日期:1998-10-01 00:00:00

  • Drug treatment of tropical parasitic infections: recent achievements and developments.

    abstract::Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060050-00002

    authors: Stephenson I,Wiselka M

    更新日期:2000-11-01 00:00:00

  • Cost effectiveness of quinolones in hospitals and the community.

    abstract::In hospitals, oral quinolone therapy has lower daily associated costs (acquisition and administration) than most intravenous regimens. In addition, oral switch therapy shortens the duration of hospital stay for most patients. However, randomised trials are required to measure the economic impact of the switch to oral ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199958002-00014

    authors: Davey P

    更新日期:1999-01-01 00:00:00